Dose ranging for trials through biomarkers of drug effects

Journal of Nutrition, Health and Aging

Volumn 14, Issue 4, 2010, Pages 310-311

  Potter, W Z ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; BIOLOGICAL MARKER; NOOTROPIC AGENT; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BRAIN TISSUE; CEREBROSPINAL FLUID ANALYSIS; DISEASE COURSE; DRUG EFFECT; HUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SHORT SURVEY; TREATMENT INDICATION; BRAIN; CEREBROSPINAL FLUID; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; PATHOLOGY; PROCEDURES;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BRAIN; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NOOTROPIC AGENTS; POSITRON-EMISSION TOMOGRAPHY;

EID: 77951873905     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12603-010-0070-5     Document Type: Short Survey

References (10)

1. Miller, G. 2009. Neuroscience Methods, Alzheimer's biomarker initiative hits its stride. Science 326: 386-389.
2. Siemers, E., Skinner, M., Dean, R.A., Gonzales, C., Satterwhite. J., Farlow, M., Ness, D., and May. P.C. 2005. Safety, tolerability, and changes in amyloid β concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 28:126-132.
3. Rosen, L.B., Stone, J.A., Plump, A., Yuan, J., Harrison, T., Flynn, M., Dallob, A., Matthews, C., Stevenson, D., Schmidt, D., et al. 2006. 04-03-02: The gamma secretase inhibitor MK-0752 acutely and significantly reduces CSF Abeta40 concentrations in humans. Alzheimer's and Dementia 2:S79-S79.
4. Bateman. R.J., Siemers, E.R., Mawuenyega, K.G., Wen, G., Browning, K.R., Sigurdson, W.C., Yarasheski, K.E., Friedrich, S.W., Demattos, R.B., May, P.C., et al. 2009. A gamma-secretase inhibitor decreases amyloid-β production in the central nervous system. Ann Neurol 66:48-54.
5. Yan, P., Bern, A.W.., Cirrito,J R., Xiao, Q., Hu, X., Want, Y., Gonzales, E., Holtzman, D.M., Lee, J-M. 2009. Characterizing the appearance and growth of amyloid plagues in APP/PS1 mice. J Neurosci 29: 10706-107 14.
6. Bateman, R.J., Munsell, L.Y., Morris, JC., Swarm, R., Yarasheski, K.E., and Holtzman. D.M. 2006. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12:856.861.
7. Bateman, R.J., Munsell, L.Y., Chen, X., Holtzman, D.M., and Yarasheski, K.E. 2007. Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J Am Soc Mass Spectrom 18:997-1006.
8. James, A.R., Nicoll. J.A.R., Barton, E., Roche, D., Neal, J.W., Ferrer, I., Thompson, P. N., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., Seubert, P., Schenk, D. and Holmes, C. 2006. A species removal After A 42 immunization. J Neuropathol Exp Neurol 65: 1040-1048
9. Siemers, ER, Friedrich, S., Dean RA, Sethuraman G, Demattos RB. Jennings D, Tamagnan G, Marek K, Seibyl J. 2008. Safety, tolerability and biomarker effects of an A monoclonal antibody administered to patients with Alzheimer's disease. Alzheimer's and Dementia: 4(Suppl 2):T774.
10. Siemers, E.R., Demattos, R.B., Friedrich, S., Dean, R.A., Sethuraman, G., Margaret, R., Jennings, D., Tamagnan, G., Marek, K., Seibyl, J. and Paul, S.M.2009. Use of a monoclonal anti-Aβ antibody with biochemical and imaging biomarkers to determine amyloid plaque load in patients with Alzheizner's Disease (AD) and control subjects. American Academy of Neurology 2009 annual meeting, Seattle, WA; IN3-2.009.